

118TH CONGRESS
1ST SESSION

H. R. 6895

To amend the National Defense Authorization Act for Fiscal Year 2023 to extend Federal support for bioindustrial manufacturing processes to include support for the manufacturing of certain pharmaceutical ingredients.

IN THE HOUSE OF REPRESENTATIVES

DECEMBER 22, 2023

Ms. SLOTKIN introduced the following bill; which was referred to the
Committee on Armed Services

A BILL

To amend the National Defense Authorization Act for Fiscal Year 2023 to extend Federal support for bioindustrial manufacturing processes to include support for the manufacturing of certain pharmaceutical ingredients.

1 *Be it enacted by the Senate and House of Representa-*
2 *tives of the United States of America in Congress assembled,*

3 **SECTION 1. SHORT TITLE.**

4 This Act may be cited as the “Defense Production
5 and Active Pharmaceutical Ingredients Act”.

1 **SEC. 2. MODIFICATION OF SUPPORT FOR RESEARCH AND**
2 **DEVELOPMENT OF BIOINDUSTRIAL MANU-**
3 **FACTURING PROCESSES.**

4 Section 215(c)(1) of the James M. Inhofe National
5 Defense Authorization Act for Fiscal Year 2023 (Public
6 Law 117–263; 10 U.S.C. 4841 note) is amended by insert-
7 ing “active pharmaceutical ingredients, key starting mate-
8 rials for such ingredients,” after “commodity chemicals,”.

○